{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:48Z","timestamp":1786988148968,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"MEF"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejps.2019.105098","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T20:02:26Z","timestamp":1572897746000},"page":"105098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis"],"prefix":"10.1016","volume":"142","author":[{"given":"Emelie","family":"Landh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn M.","family":"Moir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Gomes Dos Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7173-017X","authenticated-orcid":false,"given":"Daniela","family":"Traini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2882-1551","authenticated-orcid":false,"given":"Hui Xin","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2019.105098_bib0001","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"New Engl J. Med."},{"key":"10.1016\/j.ejps.2019.105098_bib0002","unstructured":"Bo Olsson, E.B., Lars Borgstr\u00f6m, Staffan Edsb\u00e4cker, Stefan Eirefelt, Katarina Ekelund, Lena Gustavsson, and Tove Hegelund-Myrb\u00e4ck, 2011. Controlled pulmonary drug delivery."},{"key":"10.1016\/j.ejps.2019.105098_bib0003","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10973-008-9384-5","article-title":"Physico-chemical characterization of anhydrous d-mannitol","volume":"95","author":"Bruni","year":"2009","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ejps.2019.105098_bib0004","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/jamp.2009.0757","article-title":"Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique","volume":"23","author":"Bur","year":"2010","journal-title":"J. Aerosol. Med. Pulm. Drug. Deliv."},{"key":"10.1016\/j.ejps.2019.105098_bib0005","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","article-title":"Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis","volume":"97","author":"Carsillo","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejps.2019.105098_bib0006","unstructured":"Condon, J., 2006. Surface area and porosity determinations by physisorption: measurements and theory."},{"key":"10.1016\/j.ejps.2019.105098_bib0007","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1365-2133.2009.09098.x","article-title":"Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism","volume":"160","author":"Desai","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejps.2019.105098_bib0008","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/jam.2000.13.291","article-title":"Consensus statement: aerosols and delivery devices","volume":"13","author":"Dolovich","year":"2000","journal-title":"J. Aerosol Med.-Deposit. Clearance Effec. Lung"},{"key":"10.1016\/j.ejps.2019.105098_bib0009","first-page":"369","article-title":"Development and physicochemical characterization of sirolimus solid dispersions prepared by solvent evaporation method","volume":"4","author":"Emami","year":"2014","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.ejps.2019.105098_bib0010","article-title":"Development of a physiologically-based pharmacokinetic model for Sirolimus: predicting bioavailability based on intestinal cyp3a content","volume":"2","author":"Emoto","year":"2013","journal-title":"CPT"},{"key":"10.1016\/j.ejps.2019.105098_bib0011","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMra0910061","article-title":"Airway mucus function and dysfunction","volume":"363","author":"Fahy","year":"2010","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejps.2019.105098_bib0012","article-title":"Reviewer guidance for nebulizers, metered dose inhalers","year":"1993","journal-title":"Spacer. Actuator."},{"key":"10.1016\/j.ejps.2019.105098_bib0013","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1165\/ajrcmb\/9.5.547","article-title":"Reverse transcription-polymerase chain reaction (RT-PCR) phenotypic analysis of cell cultures of human tracheal epithelium, tracheobronchial glands, and lung carcinomas","volume":"9","author":"Finkbeiner","year":"1993","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejps.2019.105098_bib0014","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1039\/jr9600003973","article-title":"Studies in adsorption: part XI. a system of classification of solution adsorption isotherms and its use in diagnosis of adsorption mechanisms and in measurement of specific surface area solids","volume":"14","author":"Giles","year":"1960","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.ejps.2019.105098_bib0015","doi-asserted-by":"crossref","first-page":"30958","DOI":"10.1074\/jbc.M202678200","article-title":"Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)","volume":"277","author":"Goncharova","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2019.105098_bib0016","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/MCB.01061-10","article-title":"mTORC2 is required for proliferation and survival of TSC2-null cells","volume":"31","author":"Goncharova","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejps.2019.105098_bib0017","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1165\/rcmb.2005-0374OC","article-title":"Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis","volume":"34","author":"Goncharova","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejps.2019.105098_bib0018","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3109\/03639041003695113","article-title":"Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model","volume":"36","author":"Haghi","year":"2010","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2019.105098_bib0019","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1016337500364","article-title":"Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration - effect of lipid composition","volume":"2","author":"Hirano","year":"1985","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105098_bib0020","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/01.pas.0000172192.25295.45","article-title":"Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis","volume":"29","author":"Kumasaka","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ejps.2019.105098_bib0021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/lrb.2009.0013","article-title":"Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC)","volume":"8","author":"Kwiatkowski","year":"2010","journal-title":"Lymphat. Res. Biol."},{"key":"10.1016\/j.ejps.2019.105098_bib0022","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105098_bib0023","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/jamp.2012.1030","article-title":"Comparison of laser diffraction measurements by Mastersizer x and Spraytec to characterize droplet size distribution of medical liquid aerosols","volume":"27","author":"Lelong","year":"2014","journal-title":"J. Aerosol. Med. Pulm. Drug. Deliv."},{"issue":"Suppl B","key":"10.1016\/j.ejps.2019.105098_bib0024","doi-asserted-by":"crossref","first-page":"B101","DOI":"10.1016\/S0149-2918(00)89027-X","article-title":"Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus","volume":"22","author":"MacDonald","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2019.105098_bib0025","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejps.2019.105098_bib0026","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1021\/js980060r","article-title":"Pulmonary delivery of nanoparticles of insoluble, iodinated ct x-ray coNtrast agents to lung draining lymph nodes in dogs","volume":"87","author":"McIntire","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105098_bib0027","doi-asserted-by":"crossref","first-page":"L703","DOI":"10.1152\/ajplung.00414.2011","article-title":"TSC2 modulates cell adhesion and migration via integrin-\u03b11\u03b21","volume":"303","author":"Moir","year":"2012","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejps.2019.105098_bib0028","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1111\/jcmm.12593","article-title":"Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on Rhoa-Gtpase and focal adhesion kinase","volume":"19","author":"Ng","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ejps.2019.105098_bib0029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11095-009-0008-y","article-title":"The application of electrostatic dry powder deposition technology to coat drug-eluting stents","volume":"27","author":"Nukala","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105098_bib0030","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s11095-011-0462-1","article-title":"Epithelial profiling of antibiotic controlled release respiratory formulations","volume":"28","author":"Ong","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105098_bib0031","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1128\/AAC.00306-13","article-title":"Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model","volume":"57","author":"Ong","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2019.105098_bib0032","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s11095-012-0827-0","article-title":"Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia","volume":"29","author":"Ong","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105098_bib0033","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejpb.2015.04.012","article-title":"Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?","volume":"93","author":"Ong","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2019.105098_bib0034","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1517\/17425247.2013.805743","article-title":"Pharmaceutical applications of the calu-3 lung epithelia cell line","volume":"10","author":"Ong","year":"2013","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.ejps.2019.105098_bib0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0304-4165(84)90214-9","article-title":"Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes","volume":"801","author":"Patel","year":"1984","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2019.105098_bib0036","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/nano6050087","article-title":"Rapamycin loaded solid lipid nanoparticles as a new tool to deliver mTOR inhibitors: formulation and in vitro characterization","volume":"6","author":"Polchi","year":"2016","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejps.2019.105098_bib0037","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425247.2014.866088","article-title":"Lymphatic system: a prospective area for advanced targeting of particulate drug carriers","volume":"11","author":"Singh","year":"2014","journal-title":"Expert Opin. Drug. Deliv."},{"key":"10.1016\/j.ejps.2019.105098_bib0038","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1086\/301804","article-title":"Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis","volume":"62","author":"Smolarek","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejps.2019.105098_bib0039","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/02652040600612439","article-title":"Polymorphic behaviour of Compritol\u00ae888 ATO as bulk lipid and as SLN and NLC","volume":"23","author":"Souto","year":"2006","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejps.2019.105098_bib0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2211068214561025","article-title":"TEER measurement techniques for in vitro barrier model systems","volume":"20","author":"Srinivasan","year":"2015","journal-title":"J. Lab. Autom."},{"key":"10.1016\/j.ejps.2019.105098_bib0041","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/943982","article-title":"Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research","volume":"2012","author":"Stewart","year":"2012","journal-title":"J. Allergy."},{"key":"10.1016\/j.ejps.2019.105098_bib0042","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1517\/21678707.2016.1148597","article-title":"Epidemiology, pathogenesis and diagnosis of lymphangioleiomyomatosis","volume":"4","author":"Taveira-DaSilva","year":"2016","journal-title":"Expert Opin. Orphan. Drugs"},{"key":"10.1016\/j.ejps.2019.105098_bib0043","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11095-015-1766-3","article-title":"Biological effects of simvastatin formulated as pMDI on pulmonary epithelial cells","volume":"33","author":"Tulbah","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105098_bib0044","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/17425247.2015.963054","article-title":"Dry powder formulation of simvastatin","volume":"12","author":"Tulbah","year":"2015","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.ejps.2019.105098_bib0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/1061186021000054933","article-title":"Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles","volume":"10","author":"Videira","year":"2002","journal-title":"J. Drug. Target"},{"key":"10.1016\/j.ejps.2019.105098_bib0046","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI200317222","article-title":"Loss of TSC1\/TSC2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR","volume":"112","author":"Zhang","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejps.2019.105098_bib0047","doi-asserted-by":"crossref","DOI":"10.1038\/sj.clpt.1996.100","article-title":"Population pharmacokinetics (PK) of sirolimus","volume":"59","author":"Zheng","year":"1996","journal-title":"Clin. Pharmacol. Therapeut."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719303719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719303719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:50:42Z","timestamp":1760529042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719303719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":47,"alternative-id":["S0928098719303719"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105098","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105098"}}